Vitamin D and prostate cancer

Urologic Clinics of North America

Volumn 29, Issue 1, 2002, Pages 95-106

  Konety, Badrinath R ^a   Getzenberg, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PROSTATE SPECIFIC ANTIGEN; SEOCALCITOL; VITAMIN D; VITAMIN D RECEPTOR;

CANCER INHIBITION; CLINICAL TRIAL; DRUG MECHANISM; GENETIC POLYMORPHISM; HUMAN; HYPERCALCEMIA; MALE; META ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

CALCITRIOL; CLINICAL TRIALS; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL;

EID: 0036304221     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(02)00021-6     Document Type: Review

References (72)

1. Structure-function relationships in the vitamin D endocrine system
2. Polymorphisms in the vitamin D receptor gene and the androgen receptor gene and the risk of benign prostatic hyperplasia
3. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)
4. Die Isolierung des antirachitischen vitamins aus Thunfischleberol
5. Two nuclear signalling pathways for vitamin D
6. Possible role for vitamin D in controlling breast cancer cell proliferation
7. Vitamin D binding protein (Gc-globulin)
8. Seasonal variation in vitamin D, vitamin D binding protein and dehydroepiandrosterone: Risk of prostate cancer in black and white men
9. Vitamin D and prostate cancer: A prediagnostic study with stored sera
10. Parathyroid hormone related protein (PTHrP) is an epidermal growth factor-regulated secretory product of human prostatic epithelial cells
11. 3 in NRP-152 rat prostatic epithelial cells
12. 3 analogs on clonal proliferation of human prostate cancer cell lines
13. 3
14. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, 1α, 25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid and phenyacelate
15. 3 metabolites
16. 3 agents in murine renal cell carcinoma
17. Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer
18. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer
19. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system
20. Calcium and fructose intake in relation to risk of prostate cancer
21. 3 (calcitriol)
22. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population
23. Geographic patterns of prostate cancer mortality: Evidence for a protective effect of ultraviolet radiation
24. 3 are mediated exclusively through the genomic signaling pathway
25. 3 in the human prostatic carcinoma cell line ALVA-31
26. 3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo
27. 3 in the androgen-dependent LNCaP cells
28. 3 in androgen-responsive LNCaP cells
29. Association of prostate cancer with vitamin D receptor haplotypes in African-Americans
30. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: Implications for association studies
31. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
32. Vitamin D receptor polymorphisms and lethal prostate cancer
33. 3 on telomerase activity and cell cycle inhibitors in human prostate cancer cell lines
34. The effect of vitamin D on the developing prostate
35. The role of vitamin D in normal prostate growth and differentiation
36. Differential effects of vitamin D on normal human prostatic epithelial and stromal cells in primary culture
37. 3 analogs: A unique class of potent inhibitors of proliferation of prostate, breast and hematopoietic cancer cells
38. 3 leads to the induced differentiation of the myelomonocytic cell line U937
39. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity
40. Vitamin D receptor polymorphisms, circulating vitamin D metabolites and risk of prostate cancer in United States physicians
41. 3 induced differentiation in a human promyelocytic leukemia cell line (HL-60): Receptor mediated maturation to macrophage-like cells
42. Experimental rickets
43. 3
44. 3 in human prostatic carcinoma cells
45. 3): Induction of apoptosis in Dunning rat prostate (MLL) and squamous cell carcinoma (SCC) models
46. 3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines
47. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)
48. 3 analogs
49. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
50. 3 on primary cultures of human prostatic cells
51. DBP-maf is a novel antiangiogenic factor that inhibits tumor growth in mice
52. Regulation of c-myc gene expression in HL-60 leukemia cells by a vitamin D metabolite
53. Drug development in prostate cancer
54. 3 and prostate cancer cell proliferation in vivo
55. Is vitamin D deficiency a risk factor for prostate cancer (hypothesis)
56. Human prostate cancer cells: Inhibition of proliferation by vitamin D analogs
57. 1α,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells
58. 3
59. Prostate cancer and the vitamin D hypothesis
60. 3
61. 3 receptors and actions in human prostate cancer cell lines
62. A phase I trial of calcitriol (1,25-dihydroxycholecalceferol) in patients with advanced malignancy
63. 3 on the metabolism of polyphosphoinositides in murine epidermal keratinocytes
64. Association of prostate cancer with vitamin D receptor gene polymorphism
65. 3 analogue EB-1089 on a human prostate cancer cell line (PC-3)
66. Significance of vitamin D receptor gene polymorphism for prostate cancer risk in Japanese
67. 2) administered daily
68. The ability of 1,25 dihydroxycholecalciferol (calcitriol) and 1,25 dihydroxy-16-ene-23-yne-cholecalciferol (analog 7553) to synergistically enhance antitumor activity in animal tumor models when combined with chemotherapeutic agents
69. 3 mediated antitumor activity with dexamethasone
70. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation
71. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines